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Genetic generalized epilepsies (GGEs) have a lifetime prevalence of 0.3% and account for 20–30% of all epi-
lepsies. Despite their high heritability of 80%, the genetic factors predisposing to GGEs remain elusive. To
identify susceptibility variants shared across common GGE syndromes, we carried out a two-stage
genome-wide association study (GWAS) including 3020 patients with GGEs and 3954 controls of European
ancestry. To dissect out syndrome-related variants, we also explored two distinct GGE subgroups compris-
ing 1434 patients with genetic absence epilepsies (GAEs) and 1134 patients with juvenile myoclonic epilepsy
(JME). Joint Stage-1 and 2 analyses revealed genome-wide significant associations for GGEs at 2p16.1
(rs13026414, Pmeta 5 2.5 3 10
29, OR[T] 5 0.81) and 17q21.32 (rs72823592, Pmeta 5 9.3 3 10
29, OR[A] 5 0.77).
The search for syndrome-related susceptibility alleles identified significant associations for GAEs at
2q22.3 (rs10496964, Pmeta 5 9.1 3 10
29, OR[T] 5 0.68) and at 1q43 for JME (rs12059546, Pmeta 5 4.1 3 10
28,
OR[G] 5 1.42). Suggestive evidence for an association with GGEs was found in the region 2q24.3
(rs11890028, Pmeta 5 4.0 3 10
26) nearby the SCN1A gene, which is currently the gene with the largest
number of known epilepsy-related mutations. The associated regions harbor high-ranking candidate
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genes: CHRM3 at 1q43, VRK2 at 2p16.1, ZEB2 at 2q22.3, SCN1A at 2q24.3 and PNPO at 17q21.32. Further rep-
lication efforts are necessary to elucidate whether these positional candidate genes contribute to the herit-
ability of the common GGE syndromes.
INTRODUCTION
Epilepsy is one of the most common neurological disorders
characterized by recurrent unprovoked seizures due to neuron-
al hyperexcitability and abnormal synchronization. Approxi-
mately 3% of the general population is affected by epilepsy
(1), which has a major impact on an individual’s quality of
life and carries significant public health consequences.
Despite advances in epilepsy research, the heterogeneous
and complex molecular mechanisms involved in epileptogen-
esis remain elusive. Genetic factors play a predominant role in
40% of epilepsies (for review, see 2). The genetic general-
ized epilepsies (GGEs, formerly called the idiopathic general-
ized epilepsies) represent the most common group of
genetically determined epilepsies accounting for 20–30% of
all epilepsies (3). The GGE syndromes are characterized by
age-related recurrent unprovoked generalized seizures in the
absence of detectable brain lesions or metabolic abnormalities
(4,5). The common classical GGE syndromes include child-
hood absence epilepsy (CAE), juvenile absence epilepsy
(JAE), juvenile myoclonic epilepsy (JME) and epilepsy with
generalized tonic–clonic seizures alone (EGTCS) (6). The
typical seizure types of the common GGE syndromes are
absence seizures (CAE and JAE), bilateral myoclonic seizures
on awakening (JME) and generalized tonic–clonic seizures
(EGTCS). The electroencephalographic signature is general-
ized spike-wave discharges, which reflect a synchronized
hyperexcitable state of thalamocortical circuits (7).
Concordance rates of 70–80% for GGE in monozygotic
twin pairs (8) compared with the rapidly declining recurrence
risk of GGEs in siblings ranging from 4 to 10% and the life-
time prevalence of 0.3% in the general population implicate
a nearly exclusively genetic etiology of GGEs but also
provide compelling evidence for a complex genetic predispos-
ition. The genetic architecture of common GGE syndromes is
likely to represent a biological spectrum, in which a small
fraction (1–2%) follows monogenic inheritance, whereas the
majority of GGE patients presumably display an oligo-/poly-
genic predisposition. Twin and family studies provide evi-
dence for genetic determinants shared across common GGE
syndromes, but also suggest that different genetic configura-
tions specify the phenotypic expression of absence and myo-
clonic seizures (8–11).
Most of the currently known genes for rare monogenic
forms of genetic epilepsies encode voltage-gated or ligand-
gated ion channels (e.g. SCN1A, GABRA1, KCNQ2,
CHRNA4) (12,13). So far, none of these epilepsy genes
seems to play a substantial role in the genetic predisposition
of common GGE syndromes. In contrast to the positional
gene mapping strategies applied in rare monogenic epilepsies,
numerous small-scale linkage and candidate gene association
studies failed to identify replicable susceptibility genes for
common GGE syndromes (14–19). Recently, success in
identifying susceptibility variants has been achieved for the
first time through an international research collaboration,
which studied more than thousand subjects with common
GGE syndromes. Large-scale copy number variation analysis
revealed a predisposing role for recurrent genomic microdele-
tions at 15q11.2, 15q13.3 and 16p13.11, which, albeit indi-
vidually rare, collectively represent important genetic risk
factors in 3% of GGE patients (20–22). These concerted re-
search efforts greatly improve the prospects of disentangling
the complex genetic basis of the common epilepsies.
Genome-wide association studies (GWAS) have attracted
considerable attention as a powerful and effective approach
for the identification of susceptibility genes in complex
human diseases (23,24). The high heritability and characteris-
tic clinical features of the common GGEs highlight these as
the most promising group of epilepsies for GWAS (25).
Here, we report the results of the first GWAS in GGEs includ-
ing 3020 GGE patients and 3954 population controls of
European ancestry. The aims of the present GWAS were to
identify susceptibility alleles shared across a wide range of
common GGE syndromes and to dissect out syndrome-related
variants conferring the risk for either genetic absence epilep-
sies (GAEs) or JME. Our GWAS results implicate susceptibil-
ity loci at 2p16.1 and 17q21.32 shared by common GGE
syndromes, and a syndrome-related locus at 2q22.3 for
GAEs and at 1q43 for JME, respectively.
RESULTS
GWAS results for GGE
The GWAS Stage-1 discovery cohort comprised 1527 GGE
patients of North-Western European descent and 2461
German population controls, matched for genetic ancestry.
After single nucleotide polymorphism (SNP) imputation and
stringent SNP quality controls, 4.56 million SNPs with an
average genotyping call rate (CR) of .99.9% were chosen
for association analysis using a linear mixed-model statistic
and complementary logistic regression analysis for an additive
genetic model to estimate odds ratios (ORs). The plot of the
genome-wide 2log10 P-values obtained for the linear mixed-
model analysis (PLMM) is shown in Figure 1A.
In the discovery stage, none of the Stage-1 SNPs achieved
genome-wide significance (PLMM , 5.0 × 1028). In total, 40
SNPs located at 14 chromosomal loci showed associations
with GGE exceeding the Stage-1 screening threshold of
PLMM , 1.0 × 1025 (Table 1; Supplementary Material,
Table S1). Four chromosomal regions with strong linkage
disequilibrium (LD) structure contained at least four SNPs
with PLMM, 1.0 × 1025: (i) 2p24.3 (SNP rs388556,
chr2:13309991; PLMM ¼ 1.1 × 1026, OR[G] ¼ 0.76, 95%-
CI: 0.68–0.84) (Supplementary Material, Fig. S3B), (ii)
2p16.1 near the gene encoding the vaccine-related serine/
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Figure 1. Genome-wide 2log10 PLMM-values of the linear mixed-model association analysis. Manhattan plots for genome-wide association analysis of 1527
GGE patients and 2461 controls (A), 702 GAE patients and 2461 controls (B) and 586 JME patients and 2461 controls (C). 2log10 PLMM-values of Stage-1
SNPs (4.5 millions) were obtained by a linear mixed-model analysis and plotted chromosome-wise against the physical position of each SNP. The triangle
refers to the Pmeta-value of the combined Stage-1 and 2 association analysis for the significantly associated SNP. The bracket connects the P-values of
Stage-1 (lower dot) and combined Stage-1 and 2 (triangle) association analyses. The blue horizontal line indicates the Stage-1 screening threshold at
PLMM ¼ 1025 and the red line the threshold for genome-wide significance at PLMM ¼ 5.0 × 1028. PLMM-values for X-chromosomal SNPs shown in
Figure 1A–C refer to females only (947 GGE/438 GAE/372 JME versus 1179 controls). Only PLMM-values ,0.05 were presented.
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threonine kinase 2 (VRK2) (SNP rs13026414, chr2:57787559;
PLMM ¼ 1.2 × 1027, OR[T] ¼ 0.78, 95%-CI 0.71–0.86)
(Fig. 2A; Supplementary Material, Fig. S3A), (iii) 14q11.2
in the 5′-terminal region of the PABPN1 gene (rs2268330,
chr14:22865816; PLMM ¼ 2.6 × 1026, OR[C] ¼ 1.30, 95%-
CI 1.17–1.44) and (iv) 17q21.32 (rs72823592,
chr17:43478003; PLMM ¼ 3.7 × 1026, OR[A] ¼ 0.74, 95%-
CI 0.66–0.83) (Fig. 2C; Supplementary Material, Fig. S3E).
Of interest, suggestive evidence for association was obtained
in the chromosomal region 2q24.3 encompassing the SCN1A
gene (rs11890028, chr2:166651523; PLMM ¼ 2.4 × 1026,
OR[G] ¼ 0.77, 95%-CI 0.70–0.85) (Fig. 2B; Supplementary
Material, Fig. S3C). The SCN1A gene encodes the neuronal
sodium channel a1 subunit (NaV1.1) and is currently the
gene with the largest number (.700) of known
epilepsy-related mutations (26).
Based on the significance of the association signals and the
regional LD structure, we selected nine top-ranked SNPs for
Stage-2 replication analysis in two independent cohorts
comprising 604 European parent–offspring trios of children
with GGE and a European case–control sample consisting
of 889 unrelated GGE patients and 889 ethnically matched
population controls (Table 2). Joint Stage-1 and 2 analysis
revealed genome-wide significant associations at 2p16.1
(SNP rs13026414, chr2:57787559; Pmeta ¼ 2.5 × 1029,
OR[T] ¼ 0.81, 95%-CI 0.76–0.87) and also 17q21.32
(rs72823592, chr17:43478003; Pmeta ¼ 9.3 × 1029, OR[A] ¼
0.77, 95%-CI 0.71–0.83).
Although Stage-2 replication analysis did not strengthen
evidence for an association of GGE with SNP rs11890028 in
the 5′-terminal SCN1A region, the combined Stage-1 and 2
P-values (top-ranked SNP: rs11890028, chr2:166651523;
Pmeta ¼ 4.0 × 1026, OR[G] ¼ 0.85, 95%-CI 0.79–0.92) em-
phasize SCN1A as potential susceptibility gene for common
GGE syndromes. In line with this finding, supportive evidence
for an association of the SNP rs11890028 with focal epilepsies
Table 1. GWAS Stage-1 SNP associations with P , 1025 based on linear mixed-model analysis
Trait Locus dbSNP ID Chr Position Minor
allele
MAF
Ca/Co
PLMM PLRgc LR OR
95%-CI
Nearest gene
GGE 1p34.3 rs1170543 1 34516971 G 0.202/0.244 7.93E206 8.15E205 0.79 (0.71–0.88) C1orf94(59.7k)
GGE 1p34.3 rs771390 1 34523523 T 0.202/0.243 8.99E206 8.63E205 0.79 (0.71–0.88) C1orf94(66.2k)
GGE 2p24.3 rs388556 2 13309991 G 0.254/0.310 1.09E206 5.10E207 0.76 (0.68–0.84)
GGE 2p23.3 rs75866363 2 23899930 A 0.099/0.067 7.48E206 3.24E206 1.52 (1.29–1.79) #ATAD2B#
GGE 2p16.1 rs13026414 2 57787559 T 0.365/0.424 1.24E207 1.61E208 0.78 (0.71–0.86)
GGE 2q24.3 rs11890028 2 166651523 G 0.260/0.312 2.37E206 5.18E207 0.77 (0.70–0.85) SCN1A(13.1k)
GGE 2q24.3 rs4667876 2 166703242 G 0.457/0.515 8.40E207 8.06E207 0.79 (0.72–0.87) SCN1A(64.8k)
GGE 3p25.2 rs17832686 3 13108902 T 0.069/0.099 7.68E206 1.70E205 0.68 (0.57–0.80)
GGE 5q22.3 rs158362 5 114121602 A 0.515/0.461 2.27E206 7.13E207 1.24 (1.13–1.36)
GGE 5q22.3 rs289034 5 114150064 T 0.432/0.378 7.57E206 1.21E206 1.25 (1.14–1.37)
GGE 11q22.3 rs11212190 11 106745947 T 0.405/0.457 8.21E206 1.25E205 0.81 (0.74–0.89) #CWF19L2#
GGE 12p13.1 rs11837280 12 13384648 G 0.195/0.237 8.49E206 6.57E205 0.78 (0.70–0.87) C12orf36(30.6k)
GGE 13q34 rs2479965 13 110788841 T 0.400/0.453 3.33E206 1.03E205 0.81 (0.74–0.88) #C13orf16#
GGE 14q11.2 rs2268330 14 22865816 C 0.261/0.214 2.62E206 1.27E206 1.30 (1.17–1.44) PABPN1(0.6k)
GGE 17q21.32 rs12951323 17 43382564 A 0.171/0.217 9.75E206 1.38E206 0.75 (0.66–0.84) PNPO(0.9k)
GGE 17q21.32 rs72823592 17 43478003 A 0.196/0.247 3.74E206 2.03E207 0.74 (0.66–0.83) NFE2L1(2.7k)
GAE 1q31.1 rs72709849 1 185133218 T 0.334/0.272 2.22E206 5.73E206 1.34 (1.18–1.53) #PLA2G4A#
GAE 1q31.1 rs12720541 1 185136695 T 0.324/0.264 6.00E206 1.55E205 1.33 (1.17–1.52) #PLA2G4A#
GAE 2p16.1 rs2717068 2 57948377 T 0.482/0.412 4.62E206 8.90E207 1.33 (1.18–1.50)
GAE 2p13.2 rs114271652 2 72990468 A 0.409/0.348 6.86E206 8.83E206 1.29 (1.15–1.46) EMX1(7.6k)
GAE 2q22.3 rs10496964 2 145076379 T 0.105/0.156 3.64E207 1.39E206 0.63 (0.52–0.76) ZEB2(82.0k)
GAE 2q22.3 rs75917352 2 145087448 T 0.116/0.169 2.77E207 7.95E207 0.65 (0.54–0.77) ZEB2(93.1k)
GAE 4q31.23 rs116127935 4 150920832 T 0.056/0.030 4.81E206 1.34E206 1.91 (1.44–2.52)
GAE 4q31.23 rs10030601 4 150944662 C 0.061/0.035 6.80E206 8.15E206 1.78 (1.36–2.32)
GAE 15q26.2 rs12904369 15 95136678 C 0.295/0.233 4.22E206 6.12E206 1.38 (1.21–1.57) SPATA8(6.8k)
GAE 16q24.2 rs8061677 16 86355067 C 0.486/0.420 7.17E206 8.19E206 1.31 (1.16–1.47) #KLHDC4#
GAE 18q12.1 rs10853686 18 24124522 T 0.364/0.432 8.87E206 3.96E206 0.75 (0.67–0.85)
JME 1q43 rs12059546 1 238036720 G 0.241/0.172 1.97E207 1.40E207 1.53 (1.32–1.79) #CHRM3#
JME 1q43 rs1110615 1 238040793 A 0.236/0.168 4.14E207 2.32E207 1.53 (1.31–1.78) #CHRM3#
JME 3q21.31 rs12635454 3 48738660 A 0.107/0.070 4.82E206 1.77E205 1.59 (1.28–1.97) IHPK2(8.9k)
JME 3q21.31 rs62261251 3 49612053 G 0.097/0.062 6.45E206 2.43E205 1.62 (1.30–2.04) #BSN#
JME 5q12.3 rs39861 5 66188014 C 0.302/0.235 2.25E207 1.05E205 1.41 (1.22–1.62) #MAST4#
JME 8q23.1 rs3019359 8 109824117 T 0.369/0.442 5.40E206 4.91E207 0.74 (0.65–0.84) TMEM74(40.4k)
JME 11p15.4 rs10836956 11 4902623 A 0.079/0.046 9.10E206 2.81E205 1.76 (1.37–2.26) OR51G1(0.5k)
JME 13q13.2 rs17669194 13 33165584 T 0.180/0.129 6.76E206 2.73E205 1.48 (1.25–1.76)
JME 18q11.2 rs6507226 18 18445289 G 0.375/0.439 7.69E206 1.37E204 0.77 (0.67–0.87)
JME 18q22.3 rs4892037 18 68574532 C 0.264/0.199 9.26E206 6.03E206 1.45 (1.25–1.68) #NETO1#
GGEs, genetic generalized epilepsies; GAEs, genetic absence epilepsies; JME, juvenile myoclonic epilepsy; dbSNP, annotation of a single nucleotide
polymorphism according to NCBI dbSNP Build 36.3; Chr, chromosome; Position, physical chromosomal position in bps; Minor allele, SNP allele with a
frequency ,50% in the entire study sample; MAF, minor allele frequency; Ca, cases; Co, control subjects; PLMM, type-1 error rate of the linear mixed-model
statistic; PLRgc, P-values of logistic regression (LR) analysis adjusted for the observed genomic inflation factor; OR, odds ratio, 95%-CI: 95%-confidence interval.
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has been published in a recent GWAS of entirely independent
cohorts, comprising 3445 European patients with various
kinds of focal epilepsies and 6935 controls of European ances-
try (16). This GWAS reported an association of P ¼ 4.8 ×
1024 for SNP rs11890028 using logistic regression analysis
for an additive genetic model. Joint association analysis of
both GWAS datasets revealed genome-wide significance for
the same risk allele of SNP rs11890028 (Pmeta ¼ 4.6 ×
1028; Stouffer’s z trend statistic).
GWAS results for GAEs
To search for susceptibility genes conferring the risk for
GAEs, a genome-wide Stage-1 association scan was carried
out in 702 patients with GAEs of North-Western European
origin and 2461 ethnically matched controls. The genome-wide
plot of the Stage-1 2log10 PLMM-values per chromosome is
shown in Figure 1B. None of the observed PLMM-values met
genome-wide significance at the discovery stage. In total, 71
SNPs exceeded the Stage-1 screening threshold of PLMM,
1.0 × 1025 (Table 1; Supplementary Material, Table S1).
Four chromosome regions of strong LD contained at least
four SNPs with PLMM, 1.0 × 1025: (i) at 1q31.1 within the
PLA2G4A gene encoding the cytosolic phospholipase A2
group 4A (rs72709849, chr1:185133218; PLMM¼ 2.2 × 1026,
OR[T] ¼ 1.34, 95%-CI: 1.18–1.53) (Supplementary Material,
Fig. S4F), (ii) at 2q22.3 (rs10496964, chr2:145076379,
PLMM ¼ 3.6 × 1027, OR[T] ¼ 0.63, 95%-CI: 0.52–0.76)
(Fig. 3A; Supplementary Material, Fig. S3H) and (iii) in the
region 4q31.23 (rs10030601, chr4:150944662; PLMM ¼ 6.8 ×
1026, OR[C] ¼ 1.78, 95%-CI: 1.36–2.32). Like in the GGE
GWAS, we observed strong association signals at 2p16.1
(rs2717068, chr2:57948377; PLMM ¼ 4.6 × 1026, OR[T] ¼
1.33, 95%-CI: 1.18–1.50).
Stage-2 replication analysis was carried out for seven
top-ranked Stage-1 SNPs with PLMM , 1.0 × 1025 in two in-
dependent replication cohorts comprising 347 parent–off-
spring trios of children with GAEs and a case–control
sample consisting of 385 European GAE patients and 385 eth-
nically matched controls. The association results of the
Stage-2 replication and joint Stage-1 and 2 analyses are
shown in Table 2. Joint Stage-1 and 2 analysis revealed a sig-
nificant association at 2q22.3 (top SNP: rs10496964,
chr2:145076379, Pmeta ¼ 9.1 × 1029, OR[T] ¼ 0.68, 95%-
CI: 0.60–0.78). Similar to the GWAS results for GGEs, the
combined Stage-1 and 2 results support an association of
GAEs with the 2p16.1 locus (rs2717068, chr2:57948377;
Pmeta ¼ 3.6 × 1027, OR[T] ¼ 1.27; 95%-CI: 1.16–1.40).
GWAS results for JME
To identify susceptibility genes conferring the risk for JME, a
genome-wide Stage-1 association scan was carried out in 586
Figure 2. Regional PLMM-values of Stage-1 SNP associations with GGE. As-
sociation results of GGE to 2p16.1 (A), 2q24.3 (B) and 17q21.32 (C). PLMM-
values of regional Stage-1 SNPs obtained by the linear mixed-model statistic
are plotted against their physical chromosomal positions (NCBI build 36.3,
hg18). The top-ranked SNP at each locus is shown in purple. The color
scheme of the SNP dots reflects the pairwise LD between the top-ranked
SNP and a neighboring SNP (pairwise r2 values are obtained from the 1000
Genomes Project HapMap CEU data (June 2010 release)). Estimated recom-
bination rates are plotted in blue. Gene and microRNA annotations are from
the UCSC genome browser (hg18). GGEs: genetic generalized epilepsies.
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Table 2. GWAS Stage-2 replication and combined association analysis of 21 top-ranked Stage-1 candidate SNPs
Stage-1 case–control cohorts Stage-2 case–control cohorts Stage-2 parent–offspring trios Stage-1 and 2 joint analysis Nearest gene
Trait dbSNP ID Chr Position A1/A2 MAF
Ca/Co
PLMM LR OR 95%-CI MAF Ca/Co PCMH OR 95%-CI T/U PTDT OR 95%-CI Pmeta OR 95%-CI
GGE rs771390 1 34523523 T/C 0.202/0.243 8.99E206 0.79 (0.71–0.88) 0.197/0.226 3.40E202 0.84 (0.71–0.99) 211/231 3.42E201 0.91 (0.76–1.10) 5.90E207 0.82 (0.76–0.89) C1orf94(66.2k)
GGE rs388556 2 13309991 G/C 0.254/0.310 1.09E206 0.76 (0.68–0.84) 0.313/0.309 7.75E201 0.98 (0.85–1.13) 262/241 3.49E201 0.92 (0.77–1.10) 8.47E205 0.88 (0.82–0.95)
GGE rs13026414 2 57787559 T/C 0.365/0.424 1.24E207 0.78 (0.71–0.86) 0.373/0.403 7.19E202 0.88 (0.77–1.01) 248/301 2.37E202 0.82 (0.70–0.97) 2.47E209 0.81 (0.76–0.87)
GGE rs11890028 2 166651523 G/T 0.260/0.312 2.37E206 0.77 (0.70–0.85) 0.300/0.317 2.58E201 0.92 (0.80–1.06) 270/271 9.66E201 1.00 (0.84–1.18) 4.02E206 0.85 (0.79–0.92) SCN1A(13.1k)
GGE rs289034 5 114150064 T/C 0.432/0.378 7.57E206 1.25 (1.14–1.37) 0.386/0.395 5.02E201 0.95 (0.83–1.10) 296/272 3.14E201 1.09 (0.92–1.28) 7.93E205 1.14 (1.06–1.22)
GGE rs2479965 13 110788841 T/C 0.400/0.453 3.33E206 0.81 (0.74–0.88) 0.449/0.452 8.58E201 0.99 (0.87–1.13) 288/281 7.69E201 1.03 (0.87–1.21) 4.39E205 0.89 (0.83–0.95) #C13orf16#
GGE rs2268330 14 22865816 C/G 0.261/0.214 2.62E206 1.30 (1.17–1.44) 0.266/0.250 3.01E201 1.08 (0.93–1.26) 209/250 5.57E202 0.84 (0.70–1.01) 5.51E205 1.14 (1.06–1.23) PABPN1(0.6k)
GGE rs12951323 17 43382564 A/C 0.171/0.217 9.75E206 0.75 (0.66–0.84) 0.179/0.209 2.18E202 0.82 (0.70–0.97) 162/184 2.37E201 0.88 (0.71–1.09) 3.25E207 0.79 (0.72–0.86) PNPO(0.9k)
GGE rs72823592 17 43478003 A/G 0.196/0.247 3.74E206 0.74 (0.66–0.83) 0.190/0.237 4.97E204 0.75 (0.64–0.88) 175/197 2.54E201 0.89 (0.72–1.09) 9.35E209 0.77 (0.71–0.83) NFE2L1(2.7k)
GAE rs12720541 1 185136695 T/G 0.324/0.264 6.00E206 1.33 (1.17–1.52) 0.277/0.252 2.72E201 1.14 (0.91–1.43) 120/128 6.12E201 0.94 (0.73–1.20) 8.59E206 1.21 (1.10–1.35) #PLA2G4A#
GAE rs1520965 2 57917252 G/T 0.368/0.299 8.47E206 1.36 (1.20–1.54) 0.367/0.304 8.69E203 1.33 (1.07–1.64) 150/139 5.18E201 1.08 (0.86–1.36) 6.59E207 1.30 (1.18–1.43)
GAE rs2717068 2 57948377 T/G 0.482/0.412 4.62E206 1.33 (1.18–1.50) 0.469/0.395 3.46E203 1.35 (1.10–1.65) 167/162 7.83E201 1.03 (0.83–1.28) 3.64E207 1.27 (1.16–1.40)
GAE rs10496964 2 145076379 T/C 0.105/0.156 3.64E207 0.63 (0.52–0.76) 0.138/0.181 2.13E202 0.72 (0.55–0.95) 88/114 6.74E202 0.77 (0.58–1.02) 9.09E209 0.68 (0.60–0.78) ZEB2(82.0k)
GAE rs10030601 4 150944662 C/T 0.061/0.035 6.80E206 1.78 (1.36–2.32) 0.064/0.058 6.70E201 1.10 (0.72–1.67) 45/26 2.41E202 1.73 (1.07–2.81) 1.27E206 1.58 (1.29–1.93)
GAE rs12904369 15 95136678 C/A 0.295/0.233 4.22E206 1.38 (1.21–1.57) 0.257/0.253 8.83E201 1.02 (0.81–1.28) 120/135 3.48E201 0.89 (0.70–1.14) 2.54E205 1.20 (1.08–1.33) SPATA8(6.8k)
GAE rs10853686 18 24124522 T/C 0.364/0.432 8.87E206 0.75 (0.67–0.85) 0.383/0.392 7.14E201 0.96 (0.78–1.18) 158/167 6.18E201 0.95 (0.76–1.18) 1.03E205 0.83 (0.75–0.91)
JME rs12059546 1 238036720 G/A 0.241/0.172 1.97E207 1.53 (1.32–1.79) 0.232/0.213 3.74E201 1.12 (0.88–1.42) 62/38 1.64E202 1.63 (1.09–2.44) 4.14E208 1.42 (1.26–1.61) #CHRM3#
JME rs1110615 1 238040793 A/G 0.236/0.168 4.14E207 1.53 (1.31–1.78) 0.229/0.205 2.72E201 1.15 (0.90–1.46) 61/37 1.53E202 1.65 (1.10–2.48) 6.56E208 1.43 (1.26–1.62) #CHRM3#
JME rs62261251 3 49612053 G/C 0.097/0.062 6.45E206 1.62 (1.30–2.04) 0.062/0.075 3.09E201 0.81 (0.54–1.21) 21/29 2.58E201 0.72 (0.41–1.27) 1.00E204 1.28 (1.06–1.54) #BSN#
JME rs39861 5 66188014 C/T 0.302/0.235 2.25E207 1.41 (1.22–1.62) 0.272/0.258 5.24E201 1.08 (0.86–1.35) 50/56 5.60E201 0.89 (0.61–1.31) 3.25E207 1.26 (1.13–1.41) #MAST4#
JME rs17669194 13 33165584 T/C 0.180/0.129 6.76E206 1.48 (1.25–1.76) 0.141/0.159 3.19E201 0.87 (0.65–1.15) 40/40 1.00E+00 1.00 (0.65–1.55) 4.10E205 1.25 (1.09–1.44)
GGEs, genetic generalized epilepsies; GAEs, genetic absence epilepsies; JME, juvenile myoclonic epilepsy; dbSNP, SNP, annotation of a single nucleotide polymorphism according to NCBI dbSNP Build 36.3; Chr, chromosome; Position, physical chromosomal
position in bps; A1/A2 SNP alleles in the entire study cohort; MAF, minor allele (A1) frequency; Ca, cases; Co, controls; PLMM, type-1 error rate of the linear mixed-model statistic; PCMH, P-value of the Cochran–Mantel–Haenszel test for 2 × 2 × 6 groups; PTDT,
P-value of the transmission disequilibrium test; Pmeta, meta-analysis of Stage-1 and 2 P-values; OR, odds ratio, 95%-CI, 95%-confidence interval. The SNPs exceeding the significance threshold of Pmeta , 5.0 × 108 in the combined Stage-1 and 2 association analysis
are marked by bold letters.
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Material, Fig. S3I), and on chromosome 5q12.3 within the
MAST4 gene encoding the microtubule-associated serine/threo-
nine kinase 4 (rs39861, chr5:66188014; PLMM ¼ 2.3 × 1027,
OR[C] ¼ 1.41, 95%-CI: 1.22–1.62) (Supplementary Material,
Fig. S3J). Furthermore, two adjacent SNPs at chromosome
3q21.31 were located in a region of strong LD harboring the
gene encoding the presynaptic scaffolding protein Bassoon
(BSN) (rs62261251, chr3:49612053, PLMM ¼ 6.5 × 1026,
OR[G] ¼ 1.62, 95%-CI: 1.30–2.04).
Stage-2 replication analysis was carried out for five
top-ranked Stage-1 SNPs with PLMM , 1.0 × 1025 in two in-
dependent replication samples comprising 166 parent–off-
spring trios of children with JME and a case–control sample
consisting of 382 European JME patients and 382 ethnically
matched controls. The association results of the Stage-2 repli-
cation and joint Stage-1 and 2 analyses are shown in Table 2.
The joint Stage-1 and 2 P-value of SNP rs12059546, which is
located in the gene encoding the M3 muscarinic acetylcholine
receptor (CHRM3), reached genome-wide significance
(rs12059546, chr1:238036720, Pmeta ¼ 4.1 × 1028, OR[G] ¼
1.42, 95%-CI: 1.26–1.61).
DISCUSSION
GGE syndromes are considered the most promising of the
common epilepsies for molecular genetic studies, because of
their high heritability, diagnostic reliability and prevalence
accounting for 20–30% of all epilepsies (2,3,13,25). Despite
their predominant genetic etiology, previous linkage and asso-
ciation studies have failed to identify replicable susceptibility
genes for common GGEs (14–19). This failure likely reflects
the underestimated degree of genetic complexity and hetero-
geneity as well as the speculative, hypothesis-driven approach
of candidate gene studies (17,18,27). Here, we report the first
GWAS for common GGEs, including 3020 GGE patients and
3954 controls all of European ancestry. This comprehensive
and hypothesis-free approach offers a powerful tool to
dissect the unknown genetic architecture of the common
GGEs.
The present GWAS revealed significant associations at
2p16.1 and 17q21.32 for GGEs, 2q22.3 for GAEs and at
1q43 for JME (Fig. 1A–C). To exclude technical artifacts,
stringent array and SNP quality filters were applied to
ensure a high accuracy of SNP genotyping. In addition, we
used a novel linear mixed-model statistic that provides a
powerful and efficient tool for accounting for all sources of
stratification in a GWAS using a case–control design (28).
Thereby, we minimized the risk of spurious associations due
to confounding by stratification effects or cryptic relatedness.
Of note, GGE was selected as target phenotype in the present
GWAS but we also explored two GGE subtypes to evaluate
the hypothesis that susceptibility alleles differentially predis-
pose to either GAEs or JME. Therefore, the interpretation of
the present association results should take into account mul-
tiple testing of two additional phenotype models in an explora-
tory approach. Considering that our GWAS will have
primarily detected those susceptibility variants enriched by
chance (‘winner’s curse’) (29), further replication efforts are
necessary to validate these novel association findings.
Specifically, further validation is required for the JME-related
association signal at 1q43 (Pmeta ¼ 4.1 × 1028), which is
close to the threshold for genome-wide significance (P,
5.0 × 1028). Of interest, an empirical evaluation of borderline
genetic associations (P-value between 1027–5.0 × 1028)
demonstrated that 70% of the investigated borderline asso-
ciations reached the significance threshold of P, 5.0 ×
1028 when additional data from subsequent GWASs were
considered (30). These empirical data may argue against con-
cerns that the traditional significance threshold of P , 5.0 ×
1028 might be too lenient. Otherwise, it is likely that we
have missed common genetic factors of low risk (ORs,
1.3) due to the modest power of the sample sizes investigated
in the present GWAS (Supplementary Material, Fig. S1).
The present GWAS in common GGEs identified two
genome-wide significant associations in the chromosomal
regions 2p16.1 and 17q21.32. The associated genomic seg-
ments harbor interesting candidate genes, which warrant
further attention. The association for GGEs/GAEs in the
chromosomal region 2p16.1 is located in an intergenic
region close to a recombination hot spot (Fig. 2A). The asso-
ciated chromosomal segment consists of 900 kb encom-
passing the genes encoding the vaccine-related serine/
threonine kinase 2 (VRK2) and the Fanconi-anemia-
complementation L polypeptide (FANCL) distally (Supple-
mentary Material, Fig. S3A). Interestingly, a recent GWAS
meta-analysis of schizophrenia revealed a genome-wide asso-
ciation near VRK2 (rs2312147, chr2:58020264; P ¼ 1.9 ×
1029, OR[C] ¼ 1.09) (31). Notably, the SNP rs2312147 is
in modest to strong LD (r2: 0.25–0.87, D′ . 0.8) with the
SNPs at 2p16.1 that display the strongest associations with
GGE and GAE. These overlapping association signals
suggest that schizophrenia and GGEs may share a genetic
risk factor at the 2p16.1 locus. An exploration of the
phenotype-deletion relationship of the 2p15-p16.1 microdele-
tion syndrome characterized by intellectual disability, micro-
cephaly and intractable seizures supports the hypothesis
that haploinsufficiency of the VRK2 gene may impair
cortical development (32–34). Thereby, VRK2-associated
neurodevelopmental alterations could increase the risk of
GAE/GGE.
The 17q21.32 locus encompasses a chromosomal segment
of 650 kb harboring 10 genes (Fig. 2C; Supplementary
Material, Fig. S3E), of which the gene encoding
pyridoxine-5′-phosphate oxidase (PNPO) represents a plaus-
ible candidate gene. PNPO catalyzes the oxidation of
pyridoxine-5′-phosphate to pyridoxal-5′-phosphate, the active
co-factor form of vitamin B6, which is involved in neurotrans-
mitter metabolism. Recessively inherited PNPO mutations
lead to a severe deficiency of pyridoxal-5′-phosphate levels
in the brain and cause neonatal and infantile seizures typically
occurring as status epilepticus during febrile episodes (35,36).
In contrast to a severe PNPO deficiency caused by highly
penetrant recessively inherited PNPO mutations, PNPO se-
quence variants with modest effects on pyridoxal-5′-phosphate
levels could result in an impaired neurotransmitter homeosta-
sis leading to an increase of seizure susceptibility. With
respect to the therapeutic implications of pyridoxal-5′-
phosphate deficiency, PNPO represents a high-priority meta-
bolic candidate gene with potential clinical relevance (37).
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Two other potential candidates at 17q21.32 are the gene
encoding the heterochromatin protein-1 (CBX1) and the gene
encoding the CDK5 regulatory subunit-associated protein 3
(CDK5RAP3); both are involved in the control of neuronal dif-
ferentiation and neuron migration during cortical development
(38,39). These neurodevelopmental alterations correspond
well with the observation of microdysgenesis of mesiofrontal
cortical structures in JME and other GGEs (40–42).
Interestingly, we found suggestive evidence for association
of GGE in the chromosomal region 2q24.3 that encompasses
the SCN1A gene (Fig. 2B; Supplementary Material,
Fig. S3C). SCN1A is a highly conserved gene encoding the
a subunit of the neuronal voltage-gated sodium channel that
plays a central role in the generation and propagation of
action potentials in both neuronal and glial cells (26).
SCN1A is currently the gene with the largest number (n.
700) of epilepsy-related mutations (for review, see 26). Muta-
tions in the SCN1A gene were identified in 10% of patients
with generalized epilepsy with febrile seizures plus (GEFS+)
and 95% of children with severe myoclonic epilepsy in
infancy (SMEI) (26,43,44). The key role of SCN1A mutations
in the expression of predominantly generalized seizures in
GEFS+ families implicates an involvement of SCN1A also
in the pathogenesis of common GGE syndromes. Consistently,
we obtained association signals achieving intermediate signifi-
cance for several SNPs at the SCN1A locus (top-ranked SNP:
rs11890028, Pmeta ¼ 4.0 × 1026). Of interest, supportive evi-
dence for an association of the SCN1A SNP rs11890028
with focal epilepsies has also been reported in a recent
GWAS of focal epilepsies (16). Joint association analysis
reaches genome-wide significance for the SNP rs11890028
(Pmeta ¼ 4.6 × 1028) emphasizing an intriguing role of
SCN1A as a genetic risk factor for a wide spectrum of
common epilepsy syndromes. Taking into account that the
top-ranked association signals are located in the intergenic
region of 135 kb between the SCN1A and SCN9A genes (Sup-
plementary Material, Fig. S3C), it is also possible that suscep-
tibility alleles at the SCN9A locus may contribute to the
association findings in the 2q24.3 region (45).
In an exploratory approach, we also addressed the question
whether susceptibility variants differentially predispose to
either GAEs or JME. Twin and family studies suggest that
heterogeneous configurations of oligo-/polygenic factors, con-
sisting of both shared and specifying susceptibility alleles, dif-
ferentially determine the expression of either typical absence
seizures (CAE and JAE) or JME-related myoclonic seizures
(8–11). Despite the relatively low numeric power of the
GAE- and JME subgroups, we presumed that a thorough de-
lineation of more homogeneous GGE phenotypes/endopheno-
types and narrowly defined inclusion criteria of GGE
subgroups may result in an enrichment of GGE
subtype-related risk factors that facilitate the dissection of
the complex and heterogeneous genetic basis of the
common GGE syndromes (17,18). In support of this assump-
tion, we found a genome-wide significant association for
GAEs in the chromosomal region 2q22.3 and for JME at
chromosome 1q43. Overall, the top-associated loci, achieving
only intermediate significance at the discovery stage, consid-
erably differed between both GGE subgroups, although the
same control cohort was used for the case–control association
analyses. However, given the limited power of both GGE sub-
groups, the top-ranked association signals do not reach signifi-
cance levels that allow clarifying the hypothesis whether
heterogeneous sets of genetic risk factors differentially
confer susceptibility to either GAEs or JME (see Fig. 1B
and C; Supplementary Material, Table S2). Nonetheless, the
current results should encourage further studies on larger
GGE cohorts to search for syndrome-related susceptibility
genes.
The significant association for GAEs in the chromosomal
region 2q22.3 is located in an intergenic region (Fig. 2A).
The nearest gene encodes the zinc finger E-box-binding
homeobox 2 protein (ZEB2) which is located 80 kb up-
stream of the top-ranked association signal (rs10496964,
Pmeta ¼ 9.1 × 1029, OR[T] ¼ 0.68). Mutations in the ZEB2
gene cause the Mowat–Wilson syndrome that is characterized
by intellectual disability, distinct facial features and congenital
anomalies such as Hirschsprung disease, congenital heart
defects, corpus callosum agenesis and urinary tract anomalies
(46). About 74% of patients with Mowat–Wilson syndrome
are also affected by epilepsy (46). This intriguing co-
morbidity emphasizes common pathogenic mechanisms that
operate in both the conditions.
The association with JME at 1q43 encompasses a chromo-
somal segment of 100 kb flanked by two recombination
hot spots. It covers the distal part of the CHRM3 gene
(Fig. 3B; Supplementary Material, Fig. S3I). Although it is
well established that mutations of genes encoding neuronal
nicotinic acetylcholine receptor subunits (CHRNA4,
CHRNB2) cause autosomal dominant nocturnal frontal lobe
epilepsy (for review, see 47), it remains to be determined
whether genes encoding muscarinic acetylcholine receptors
also play a role in epileptogenesis. Muscarinic effects on stri-
atal cholinergic interneurons modulate thalamic gating of cor-
ticostriatal signaling (48). More specifically, the hippocampal
CA3 transcriptome signature in surgically removed sclerotic
hippocampi of patients with refractory mesial temporal lobe
epilepsy revealed a cell-type specific expression of the M3
muscarinic acetylcholine receptor in distinct subtypes of hip-
pocampal interneurons, providing a molecular mechanism
for a differential cholinergic modulation of hippocampal cir-
cuitry (49,50) which may influence synchronization and excit-
ability of thalamocortical circuits and thereby seizure
susceptibility (7,50). However, muscarinic M3-receptor
knockout mice do not show increased pilocarpine-induced
seizure activity (51).
In summary, we present the first GWAS of GGE syndromes,
the most common form of all inherited epilepsies, and report
allelic associations at 1q43, 2p16.1, 2q22.3, 2q24.3 and
17q21.3. The associated regions harbor high-ranking candi-
date genes: CHRM3 at 1q43, VRK2 at 2p16.1, ZEB2 at
2q22.3 and PNPO at 17q21.32. In context with the causative
role of SCN1A mutations in GEFS+ and SMEI (43,44), our
results provide emerging evidence that susceptibility variants
of the SCN1A gene may also increase the risk of common
GGE syndromes. Further replication studies are necessary to
validate these novel association findings and to delineate
their phenotype–genotype relationships.
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MATERIALS AND METHODS
Study participants
Epilepsy patients of European ancestry with common GGE
syndromes (CAE, JAE, JME and EGTCS alone with
age-at-onset ,26 years) were recruited as a concerted effort
of national and international epilepsy genetics programs inte-
grated in the European EPICURE Project (http://www.ep
icureproject.eu). Phenotyping and diagnostic classification of
GGE syndromes were carried out according to standardized
protocols (available at: http://portal.ccg.uni-koeln.de/ccg/
research/epilepsy-genetics/sampling-procedure) (4–6) and
were reviewed by experienced epileptologists. Individuals
with a history of severe major psychiatric disorders (autism
spectrum disorder, schizophrenia, affective disorder: recurrent
episodes requiring pharmacotherapy or treatment in a hos-
pital), or severe intellectual disability (no basic education, per-
manently requiring professional support in their daily life)
were excluded. The study protocol was approved by the
local institutional review boards and all study participants
gave informed consent.
The GWAS followed a two-stage process (52): Stage-1,
high-density SNP association scan in a case–control discovery
sample; followed by Stage-2 replication and joint (Stage-1 and
2) association analysis of the Stage-1 association signals
exceeding PLMM , 1.0 × 1025 in two independent replication
samples of European ancestry.
Stage-1 GGE discovery sample
After quality control (QC) of the individual array data, 1527
unrelated patients with GGE (947 females/580 males) and
2461 German population controls (1179 females/1282 males)
were included in the genome-wide high-density SNP scan.
The GGE patients had the following syndromes: CAE n ¼
480, JAE n ¼ 215, unspecified GAE n ¼ 7, JME n ¼ 586,
EGTCS on awakening n ¼ 93 and EGTCS alone n ¼ 146.
The origins of these subjects, by country, were: Austria n ¼
231, Belgium n ¼ 41, Denmark n ¼ 93, Germany n ¼ 885
and The Netherlands n ¼ 277. Array SNP data of 2461
German control subjects were obtained from the PopGen
Biobank and the KORA (Cooperative Health Research in the
Region of Augsburg) research platform representing epide-
miologically recruited cohorts from the Northern (Schleswig,
PopGen, n ¼ 1080) and Southern (Augsburg, KORA, n ¼
1381) regions of Germany. Although the control subjects
were not screened for epilepsy, the loss of power is likely to
be minimal as the prevalence of GGEs is only 0.3% (50).
Stage-1 GGE discovery subgroups
To dissect out susceptibility alleles differentially conferring
the risk for either GAE or JME, we formed two distinct
GGE subgroups consisting of: (i) 702 patients with GAEs
(CAE/JAE/unspecified GAE; 438 females/264 males)
without JME; and (ii) 586 patients with JME (372 females/
214 males) irrespective of whether absence seizures occurred.
For the association analyses, each group of GGE patients was
compared with the entire sample of 2461 controls.
Stage-2 replication cohorts
The Stage-2 replication cohorts comprised 604 European
parent–offspring trios of children with GGEs (378 females/
226 males; syndrome classification: CAE/JAE n ¼ 347, JME
n ¼ 166, EGTCS alone n ¼ 91; origins by country: Australia/
UK n ¼ 135, Bosnia/Croatia n ¼ 4, Bulgaria n ¼ 4, Denmark
n ¼ 31, Finland n ¼ 10, France n ¼ 18, Germany n ¼ 12,
Greece n ¼ 1, Italy n ¼ 260, Spain n ¼ 5, Sweden n ¼ 1, The
Netherlands n ¼ 5, Turkey n ¼ 118), and a case–control
sample of European descent consisting of 889 patients with
GGEs (571 females/318 males; syndrome classification: CAE/
JAE n ¼ 385, JME n ¼ 382, EGTCS alone n ¼ 122; origins
by country: Australia/UK n ¼ 264, Denmark n ¼ 44, Finland
n ¼ 6, France n ¼ 114, Germany n ¼ 130, Italy n ¼ 79, Spain
n ¼ 53, The Netherlands n ¼ 39, Turkey n ¼ 160) and 889 eth-
nically matched control subjects (398 females/491 males). The
Stage-2 GAE subgroup included 347 trios and 385 GAE patients
and 385 ethnically matched controls. The Stage-2 JME sub-
group consisted of 166 trios and 382 JME singletons and 382
ethnically matched controls.
Array quality control and population stratification analysis
Initially, the Stage-1 case–control sample consisted of 1595
GGE patients of North-Western European descent and 2518
unselected German population controls. DNA was extracted
from blood samples and lymphoblastoid cell lines using stand-
ard procedures. All Stage-1 DNA samples were genotyped by
the Affymetrix Genome-Wide Human SNP Array 6.0 (Affy-
metrix SNP 6.0 array; Affymetrix, Santa Clara, CA, USA) at
either the Affymetrix Genotyping Service (Santa Clara) or
ATLAS Biolabs (Berlin, Germany). We removed 125 subjects
(68 cases and 57 controls) from the Stage-1 case–control
sample according to four QC criteria: (i) discordant gender
information (n ¼ 1); (ii) overall SNP CR ,95% or excessive
heterozygosity rate of autosomal SNPs .29.5% (n ¼ 1); (iii)
duplicated or related individuals exceeding an identity-
by-state (IBS) allele sharing .1.55 (n ¼ 12); (iv) ancestry
outliers identified by IBS outlier detection diagnostics (propor-
tion of significantly different other samples .25%; n ¼ 82)
and subsequently by multidimensional scaling (MDS) analysis
of IBS genetic distances (n ¼ 29) using PLINK (53). After
quality control, the GWAS Stage-1 discovery sample included
1527 GGE patients and 2461 genetically matched controls.
SNP genotype quality control and SNP imputation
Stage-1 SNP 6.0 array genotyping
Genome-wide genotyping of .906 600 SNPs was performed
using the Birdseed v2 algorithm implemented in the Affyme-
trix Genotyping Console 4.0 (genotype confidence score:
,0.1, annotation file: GenomeWideSNP_6.na30, NCBI build
36.3) (54). SNP genotyping was carried out separately for
10 batches, each representing array assemblies processed at
different time points or locations. SNPs with high genotyping
accuracy were selected for SNP imputation according to the
following QC criteria: (i) minor allele frequency (MAF)
,5% in cases or controls, (ii) CR ,98% for SNPs with
MAF .10% and CR ,99% for SNPs with MAF ,10% in
either cases or controls, (ii) difference of missing data .1%
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between the cases and controls, (iv) deviation from the
Hardy–Weinberg equilibrium (HWE) with P, 1.0 × 1024
in the controls and (v) differences in the allele frequencies
with P , 1.0 × 1024 across three batches of cases and
between two batches of controls (KORA and PopGen).
Finally, the intensity cluster plots of the top-ranked associated
SNPs (P , 1.0 × 1025) of a provisional association analysis
were checked manually for clustering errors. After QC,
572 071 autosomal SNPs with an overall genotyping CR of
99.74% were used for SNP imputation to maximize genomic
coverage.
SNP imputation
SNP imputation was performed using a Markov chain Monte
Carlo algorithm implemented in the software program
IMPUTE version 2 (55). SNP imputation was based on filtered
reference haplotypes from the HapMap III CEU samples
(release #2, February 2009) and the 1000 Genomes low-
coverage CEU pilot haplotypes (NCBI Build 36.3, released
June 2010). Imputed SNPs were excluded according to the fol-
lowing QC filters: (a) IMPUTE info quality score ≤0.8, (b)
overall CR ,99%, (c) MAF ,3% in cases or controls and
(d) significant HWE deviation with P , 1026 in the cases
and P , 1024 in the controls. After QC filtering, the expanded
GWAS Stage-1 SNP dataset included 4.56 million SNPs.
Stage-2 SNP selection and genotyping
For Stage-2 replication analysis, we selected 22 Stage-1 SNPs
(12 SNPs genotyped by the SNP 6.0 array, 10 untyped SNPs
with imputed genotypes) based on their statistical significance
(PLMM , 1.0 × 1025), the regional LD structure and the
imputed information quality score (cut-off: ≥0.9). Genotyping
of the Stage-2 SNPs was performed by the Sequenom iPLEX
Gold system (Sequenom, Inc., San Diego, CA, USA) using
matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (56) at the genotyping plat-
form at the Institute of Clinical Molecular Biology (University
Medical Center Schleswig-Holstein, Kiel, Germany). Two
SNPs (SNP ID: rs1110615, assay-ID: C___7539479_10;
rs17669194, C__34702952_10) were genotyped by
TaqManw SNP genotyping assays according to the manufac-
turer’s instructions (Life Technologies, Carlsbad, CA, USA).
To assess the accuracy of Stage-1 and 2 SNP genotyping,
112 Stage-1 sample replicates and 68 Stage-2 sample dupli-
cates were genotyped in the Stage-2 replication analysis. For
the imputed Stage-1 SNP genotypes, the individual genotype
with the highest posterior probability was selected using a
cut-off threshold of at least 0.4. The comparison of Stage-1
and Stage-2 SNP genotypes revealed a critical concordance
rate of 96% for SNP rs4667876. Therefore, this SNP was
removed from Stage-2 analysis. The remaining 21 Stage-2
SNPs showed an allelic replication rate of .99.5% with an
average concordance rate of 99.8%. For the 68 Stage-2
sample duplicates, the SNP genotype concordance rate was
100%. Overall, we observed one Mendelian error in 604
parent–offspring trios. Altogether, these quality checks dem-
onstrate a high genotyping accuracy of the SNPs selected for
Stage-2 replication analysis.
Association analyses and controlling for population
structure
Genome-wide Stage-1 association analysis of the imputed
SNPs was performed for genotype dosages using SNPTESTv2
(www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html),
which incorporates information about uncertainties of geno-
type callings (57). To correct for potential confounding
effects of population stratification, we applied logistic regres-
sion analysis, assuming an additive model adjusted for gender
and the top four dimensions of PLINK MDS analysis as cov-
ariates. Despite this attempt to correct for structure using MDS
components, the quantile–quantile (QQ) plots of the P-values
obtained by logistic regression analysis still showed a substan-
tial overall inflation of the test statistic resulting in a genomic
inflation factor of lGC ¼ 1.11 (lGC1000 ¼ 1.06) for the Stage-1
GGE-, lGC ¼ 1.05 (lGC1000 ¼ 1.05) for the GAE- and lGC ¼
1.06 (lGC1000 ¼ 1.06) for the JME case–control samples. To
correct for the residual inflation of the test statistic, the
observed lGC was used to adjust the type-I error rates of logis-
tic regression analysis (Pgc) (52). Although genomic inflation
is expected to some extent in the presence of polygenic inher-
itance (58), some unexplained inflation could not be removed
by logistic regression analysis. To remove any residual infla-
tion of the test statistic, we applied a novel factored spectrally
transformed linear mixed-model (FaST-LMM; http://mscomp
bio.codeplex.com) that explicitly captures all sources of struc-
ture based on estimates of the genetic relatedness of indivi-
duals (28). Therefore, a covariance matrix R was generated
by calculating for every pair of individuals the genome-wide
averaged correlation of their relatedness based on 238 K high-
quality SNPs. Thereby, the genomic inflation was almost
eliminated, resulting in lGC ¼ 1.006 for the Stage-1 GGE-,
lGC ¼ 0.988 for the GAE- and lGC ¼ 0.999 for the JME
case–control samples (Supplementary Material, Fig. S2A–
C). Association analysis of genotyped X-chromosomal SNPs
was restricted to female subjects only. To adjust for multiple
testing of 4.56 million correlated SNPs, we assessed the ef-
fective number of independent tests using the software tool
‘Genetic type-1 error calculator’ (59). In total, we carried
out 764 825 independent tests per phenotype, corresponding
to a nominal significance threshold of P 6.5 × 1028 to
achieve a genome-wide type-1 error rate of P ¼ 0.05. Accord-
ingly, the threshold for genome-wide significance was set to a
nominal P-value of ,5.0 × 1028. Regional visualization of
GWAS results was produced by the program LocusZoom
version 1.1 (60). GWAS Manhattan plots were generated
using Haploview 4.2 (61). SNP and gene annotations refer
to NCBI build 36.3/UCSC hg18.
Power calculations
Power calculations were performed using a CaTS power cal-
culator (62). Joint analysis of the GWAS Stage-1 and 2
GGE samples has a power of 80% to detect a variant with
an OR of ≥1.31 at a type-I error rate of P ¼ 5.0 × 1028, as-
suming a disease prevalence of 0.3%, an additive genetic
model, a strong LD (r2 ¼ 1) between the causal variant and
the SNP allele, and a frequency of the disease-associated
allele of at least 20% in controls. Likewise, 80% power was
obtained for OR .1.44 in GAE and for OR .1.50 in JME.
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More comprehensive power simulations are provided in the
Supplementary Material, Figure S1.
Stage-2 replication and joint Stage-1 and 2 association
analyses
PLINK was utilized for single marker association analysis
using the transmission disequilibrium test (TDT) for the
parent–offspring trios and the Cochran–Mantel–Haenszel
test for 2 × 2 × 6 stratified case–control subsamples deriving
from six different European regions. The Breslow–Day test
was applied to test differences in the ORs across the stratified
subsamples. The weighted Stouffer’s z trend method was used
for joint analysis of Stage-1 and 2 P-values using the MetaP
software (http://compute1.lsrc.duke.edu/softwares/MetaP/m
etap.php) (63). The inverse variance method was applied for
combining ORs and 95%-CIs utilizing the statistical package
‘meta’ in R version 2.13.2. With respect to the relative low
power of the Stage-2 replication cohorts, association analysis
was based on joint Stage-1 and 2 analysis, which almost
always has a superior power compared with Stage-2 analysis
alone as replication study for Stage-1 association (62).
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG online.
ACKNOWLEDGMENTS
We thank all participants and their families for participating in
this study. We gratefully acknowledge the excellent technical
assistance of Sebastian Fey, Christian Becker, Ingelore
Ba¨ßmann and Kerstin Wodecki in array processing and high-
throughput SNP genotyping. The Dutch NIGO program
(Dutch IGE Genetics Research) thanks all participants and
contributing neurologists.
Conflict of Interest statement. None declared.
FUNDING
This work was supported by grants from the European
Community (FP6 Integrated Project EPICURE, grant
LSHM-CT-2006-037315 to D.L., H.L., C.E.E., R.G., A-E.L.,
J.S., E.L., F.R., U.O., T.S., FP6 MEXCT visual sensitivity,
024224 to D.K.-N.T.); the German Research Foundation
(grants SA434/4-2, SA434/5-1 to T.S., BE3828/4-1 to T.B.);
the German Federal Ministry of Education and Research, Na-
tional Genome Research Network (NGFN-2: NeuroNet to
C.E.E., H.L. and T.S.; NGFNplus: EMINet, grants
01GS08120 to P.N. and T.S., and 01GS08123 to H.L.;
IntenC, TUR 09/I10 to T.S.); the German Society for Epilep-
tology/German chapter of the ILAE (DGfE: to H.L. and
Y.W.); the Belgian National Fund for Scientific Research
(Flanders, grant 0399.08 to P.D.J.); the Research Fund of the
University of Antwerp (IWS BOF UA 2008 to A.J. and
P.D.J.); the National Science Fund, Bulgarian Ministry of
Education, Youth and Science (grant DTK02/67 to A.J.);
The Netherlands National Epilepsy Fund (grant 04-08 to
B.P.C.K. and D.L.); The Netherlands Organization for
Scientific Research (grant 917.66.315 to B.P.C.K. and
C.G.F.d.K.); the PopGen biobank (grant to A.F.); Spanish
Ministry of Education and Science (grant SAF2007-61003 to
J.M.S); the Scientific and Technological Research Council of
Turkey (TUBITAK grant 106S027 to H.C.) and Bogazici Uni-
versity Research Fund (grants 05HB104D, 06B107D and
08HB104D to H.C.); the National Health and Medical Re-
search Council (Australia) (grant to L.M.D., S.M., S.B.,
K.O., I.E.S. and S.F.B.). The PopGen project received infra-
structure support through the German Research Foundation
excellence cluster ‘Inflammation at Interfaces’. The KORA re-
search platform (KORA, Cooperative Research in the Region
of Augsburg) was initiated and financed by the Helmholtz
Zentrum Mu¨nchen–German Research Center for Environmen-
tal Health, which is funded by the German Federal Ministry of
Education and Research and by the State of Bavaria; this re-
search was supported within the Munich Center of Health
Sciences (MC Health) as part of LMUinnovativ.
REFERENCES
1. Hauser, W.A., Annegers, J.F. and Kurland, L.T. (1993) Incidence of
epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984.
Epilepsia, 34, 453–468.
2. Helbig, I., Scheffer, I.E., Mulley, J.C. and Berkovic, S.F. (2008)
Navigating the channels and beyond: unravelling the genetics of the
epilepsies. Lancet Neurol., 7, 231–245.
3. Jallon, P., Loiseau, P. and Loiseau, J. (2001) Newly diagnosed
unprovoked epileptic seizures: presentation at diagnosis in CAROLE
study. Coordination Active du Re´seau Observatoire Longitudinal de l’
Epilepsie. Epilepsia, 42, 464–475.
4. Proposal for revised classification of epilepsies and epileptic syndromes.
Commission on Classification and Terminology of the International
League Against Epilepsy (1989). Epilepsia, 30, 389–399.
5. Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, J.H., van
Emde Boas, W., Engel, J., French, J., Glauser, T.A., Mathern, G.W. et al.
(2010) Revised terminology and concepts for organization of seizures and
epilepsies: report of the ILAE Commission on Classification and
Terminology, 2005–2009. Epilepsia, 51, 676–685.
6. Nordli, D.R. Jr (2005) Idiopathic generalized epilepsies recognized by the
International League Against Epilepsy. Epilepsia, 46(Suppl. 9), 48–56.
7. Blumenfeld, H. (2005) Cellular and network mechanisms of spike-wave
seizures. Epilepsia, 46(Suppl. 9), 21–33.
8. Berkovic, S.F., Howell, R.A., Hay, D.A. and Hopper, J.L. (1998)
Epilepsies in twins: genetics of the major epilepsy syndromes. Ann.
Neurol., 43, 435–445.
9. Marini, C., Scheffer, I.E., Crossland, K.M., Grinton, B.E., Phillips, F.L.,
McMahon, J.M., Turner, S.J., Dean, J.T., Kivity, S., Mazarib, A. et al.
(2004) Genetic architecture of idiopathic generalized epilepsy: clinical
genetic analysis of 55 multiplex families. Epilepsia, 45, 467–478.
10. Winawer, M.R., Marini, C., Grinton, B.E., Rabinowitz, D., Berkovic, S.F.,
Scheffer, I.E. and Ottman, R. (2005) Familial clustering of seizure types
within the idiopathic generalized epilepsies. Neurology, 65, 523–528.
11. Kinirons, P., Rabinowitz, D., Gravel, M., Long, J., Winawer, M.,
Se´ne´chal, G., Ottman, R. and Cossette, P. (2008) Phenotypic concordance
in 70 families with IGE-implications for genetic studies of epilepsy.
Epilepsy Res., 82, 21–28.
12. Reid, C.A., Berkovic, S.F. and Petrou, S. (2009) Mechanisms of human
inherited epilepsies. Prog. Neurobiol., 87, 41–57.
13. Gardiner, M. (2005) Genetics of idiopathic generalized epilepsies.
Epilepsia, 46(Suppl. 9), 15–20.
14. Hempelmann, A., Taylor, K.P., Heils, A., Lorenz, S., Prud’homme, J.-F.,
Nabbout, R., Dulac, O., Rudolf, G., Zara, F., Bianchi, A. et al. (2006)
Exploration of the genetic architecture of idiopathic generalized
epilepsies. Epilepsia, 47, 1682–1690.
15. Cavalleri, G.L., Weale, M.E., Shianna, K.V., Singh, R., Lynch, J.M.,
Grinton, B., Szoeke, C., Murphy, K., Kinirons, P., O’Rourke, D. et al.
(2007) Multicentre search for genetic susceptibility loci in sporadic
5370 Human Molecular Genetics, 2012, Vol. 21, No. 24
epilepsy syndrome and seizure types: a case–control study. Lancet
Neurol., 6, 970–980.
16. Kasperaviciu¯te, D., Catarino, C.B., Heinzen, E.L., Depondt, C., Cavalleri,
G.L., Caboclo, L.O., Tate, S.K., Jamnadas-Khoda, J., Chinthapalli, K.,
Clayton, L.M.S. et al. (2010) Common genetic variation and susceptibility
to partial epilepsies: a genome-wide association study. Brain, 133,
2136–2147.
17. Tan, N.C.K. and Berkovic, S.F. (2010) The Epilepsy Genetic Association
Database (epiGAD): analysis of 165 genetic association studies,
1996–2008. Epilepsia, 51, 686–689.
18. Greenberg, D.A. and Subaran, R. (2011) Blinders, phenotype, and
fashionable genetic analysis: a critical examination of the current state of
epilepsy genetic studies. Epilepsia, 52, 1–9.
19. Poduri, A. and Lowenstein, D. (2011) Epilepsy genetics—past, present,
and future. Curr. Opin. Genet. Dev., 21, 325–332.
20. Helbig, I., Mefford, H.C., Sharp, A.J., Guipponi, M., Fichera, M., Franke,
A., Muhle, H., de Kovel, C., Baker, C., von Spiczak, S. et al. (2009)
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy.
Nat. Genet., 41, 160–162.
21. de Kovel, C.G.F., Trucks, H., Helbig, I., Mefford, H.C., Baker, C., Leu,
C., Kluck, C., Muhle, H., von Spiczak, S., Ostertag, P. et al. (2010)
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to
idiopathic generalized epilepsies. Brain, 133, 23–32.
22. Mefford, H.C., Muhle, H., Ostertag, P., von Spiczak, S., Buysse, K.,
Baker, C., Franke, A., Malafosse, A., Genton, P., Thomas, P. et al. (2010)
Genome-wide copy number variation in epilepsy: novel susceptibility loci
in idiopathic generalized and focal epilepsies. PLoS Genet., 6, e1000962.
23. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P.,
Collins, F.S. and Manolio, T.A. (2009) Potential etiologic and functional
implications of genome-wide association loci for human diseases and
traits. Proc. Natl Acad. Sci. USA, 106, 9362–9367.
24. Manolio, T.A. (2010) Genomewide association studies and assessment of
the risk of disease. N. Engl. J. Med., 363, 166–176.
25. Mullen, S.A., Crompton, D.E., Carney, P.W., Helbig, I. and Berkovic, S.F.
(2009) A neurologist’s guide to genome-wide association studies.
Neurology, 72, 558–565.
26. Escayg, A. and Goldin, A.L. (2010) Sodium channel SCN1A and
epilepsy: mutations and mechanisms. Epilepsia, 51, 1650–1658.
27. Klassen, T., Davis, C., Goldman, A., Burgess, D., Chen, T., Wheeler, D.,
McPherson, J., Bourquin, T., Lewis, L., Villasana, D. et al. (2011) Exome
sequencing of ion channel genes reveals complex profiles confounding
personal risk assessment in epilepsy. Cell, 145, 1036–1048.
28. Lippert, C., Listgarten, J., Liu, Y., Kadie, C.M., Davidson, R.I. and
Heckerman, D. (2011) FaST linear mixed models for genome-wide
association studies. Nat. Methods, 8, 833–835.
29. Kraft, P. (2008) Curses–winner’s and otherwise– –in genetic
epidemiology. Epidemiology, 19, 649–651.
30. Panagiotou, O.A. and Ioannidis, J.P. and Genome-Wide Significance
Project. (2012) What should the genome-wide significance threshold be?
Empirical replication of borderline genetic associations. Int. J. Epidemiol.,
41, 273–286.
31. Steinberg, S., de Jong, S., Andreassen, O.A., Werge, T., Børglum, A.D.,
Mors, O., Mortensen, P.B., Gustafsson, O., Costas, J., Pietila¨inen, O.P.H.
et al. (2011) Common variants at VRK2 and TCF4 conferring risk of
schizophrenia. Hum. Mol. Genet., 20, 4076–4081.
32. Chandler, K.E., Del Rio, A., Rakshi, K., Springell, K., Williams, D.K.,
Stoodley, N., Woods, C.G. and Pilz, D.T. (2006) Leucodysplasia,
microcephaly, cerebral malformation (LMC): a novel recessive disorder
linked to 2p16. Brain, 129, 272–277.
33. Rajcan-Separovic, E., Harvard, C., Liu, X., McGillivray, B., Hall, J.G.,
Qiao, Y., Hurlburt, J., Hildebrand, J., Mickelson, E.C.R., Holden, J.J.A.
et al. (2007) Clinical and molecular cytogenetic characterisation of a
newly recognised microdeletion syndrome involving 2p15–16.1. J. Med.
Genet., 44, 269–276.
34. Chabchoub, E., Vermeesch, J.R., de Ravel, T., de Cock, P. and Fryns, J.-P.
(2008) The facial dysmorphy in the newly recognised microdeletion
2p15-p16.1 refined to a 570kb region in 2p15. J. Med. Genet., 45,
189–192.
35. Mills, P.B., Surtees, R.A.H., Champion, M.P., Beesley, C.E., Dalton, N.,
Scambler, P.J., Heales, S.J.R., Briddon, A., Scheimberg, I., Hoffmann,
G.F. et al. (2005) Neonatal epileptic encephalopathy caused by mutations
in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum.
Mol. Genet., 14, 1077–1086.
36. Musayev, F.N., Di Salvo, M.L., Saavedra, M.A., Contestabile, R., Ghatge,
M.S., Haynes, A., Schirch, V. and Safo, M.K. (2009) Molecular basis of
reduced pyridoxine 5′-phosphate oxidase catalytic activity in neonatal
epileptic encephalopathy disorder. J. Biol. Chem., 284, 30949–30956.
37. Plecko, B. and Sto¨ckler, S. (2009) Vitamin B6 dependent seizures.
Can. J. Neurol. Sci., 36(Suppl. 2), S73–S77.
38. Wang, X., Ching, Y.P., Lam, W.H., Qi, Z., Zhang, M. and Wang, J.H.
(2000) Identification of a common protein association region in the
neuronal Cdk5 activator. J. Biol. Chem., 275, 31763–31769.
39. Aucott, R., Bullwinkel, J., Yu, Y., Shi, W., Billur, M., Brown, J.P.,
Menzel, U., Kioussis, D., Wang, G., Reisert, I. et al. (2008) HP1-beta is
required for development of the cerebral neocortex and neuromuscular
junctions. J. Cell Biol., 183, 597–606.
40. Meencke, H.J. and Veith, G. (1999) The relevance of slight migrational
disturbances (microdysgenesis) to the etiology of the epilepsies. Adv.
Neurol., 79, 123–131.
41. Woermann, F.G., Free, S.L., Koepp, M.J., Sisodiya, S.M. and Duncan, J.S.
(1999) Abnormal cerebral structure in juvenile myoclonic epilepsy
demonstrated with voxel-based analysis of MRI. Brain, 122, 2101–2108.
42. Vollmar, C., O’Muircheartaigh, J., Barker, G.J., Symms, M.R.,
Thompson, P., Kumari, V., Duncan, J.S., Janz, D., Richardson, M.P. and
Koepp, M.J. (2011) Motor system hyperconnectivity in juvenile
myoclonic epilepsy: a cognitive functional magnetic resonance imaging
study. Brain, 134, 1710–1719.
43. Gambardella, A. and Marini, C. (2009) Clinical spectrum of SCN1A
mutations. Epilepsia, 50(Suppl. 5), 20–23.
44. Zuberi, S.M., Brunklaus, A., Birch, R., Reavey, E., Duncan, J. and Forbes,
G.H. (2011) Genotype–phenotype associations in SCN1A-related
epilepsies. Neurology, 76, 594–600.
45. Singh, N.A., Pappas, C., Dahle, E.J., Claes, L.R., Pruess, T.H., De Jonghe,
P., Thompson, J., Dixon, M., Gurnett, C., Peiffer, A. et al. (2009) A role of
SCN9A in human epilepsies, as a cause of febrile seizures and as a
potential modifier of Dravet syndrome. PLoS Genet., 5, e1000649.
46. Garavelli, L., Zollino, M., Mainardi, P.C., Gurrieri, F., Rivieri, F., Soli, F.,
Verri, R., Albertini, E., Favaron, E., Zignani, M. et al. (2009) Mowat–
Wilson syndrome: facial phenotype changing with age: study of 19 Italian
patients and review of the literature. Am. J. Med. Genet. A., 149A,
417–426.
47. Steinlein, O.K. and Bertrand, D. (2010) Nicotinic receptor
channelopathies and epilepsy. Pflugers Arch., 460, 495–503.
48. Ding, J.B., Guzman, J.N., Peterson, J.D., Goldberg, J.A. and Surmeier,
D.J. (2010) Thalamic gating of corticostriatal signaling by cholinergic
interneurons. Neuron, 67, 294–307.
49. Cea-del Rio, C.A., Lawrence, J.J., Tricoire, L., Erdelyi, F., Szabo, G. and
McBain, C.J. (2010) M3 muscarinic acetylcholine receptor expression
confers differential cholinergic modulation to neurochemically distinct
hippocampal basket cell subtypes. J. Neurosci., 30, 6011–6024.
50. Bando, S.Y., Alegro, M.C., Amaro, E. Jr, Silva, A.V., Castro, L.H., Wen,
H.T., Lima, L.A., Brentani, H. and Moreira-Filho, C.A. (2011)
Hippocampal CA3 transcriptome signature correlates with initial
precipitating injury in refractory mesial temporal lobe epilepsy. PLoS
One, 6, e26268.
51. Bymaster, F.P., Carter, P.A., Yamada, M., Gomeza, J., Wess, J.,
Hamilton, S.E., Nathanson, N.M., McKinzie, D.L. and Felder, C.C. (2003)
Role of specific muscarinic receptor subtypes in cholinergic
parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and
pilocarpine-induced seizure activity. Eur. J. Neurosci., 17, 1403–1410.
52. McCarthy, M.I., Abecasis, G.R., Cardon, L.R., Goldstein, D.B., Little, J.,
Ioannidis, J.P.A. and Hirschhorn, J.N. (2008) Genome-wide association
studies for complex traits: consensus, uncertainty and challenges. Nat.
Rev. Genet., 9, 356–369.
53. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R.,
Bender, D., Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J. et al.
(2007) PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am. J. Hum. Genet., 81, 559–575.
54. Rabbee, N. and Speed, T.P. (2006) A genotype calling algorithm for
Affymetrix SNP arrays. Bioinformatics, 22, 7–12.
55. Howie, B.N., Donnelly, P. and Marchini, J. (2009) A flexible and accurate
genotype imputation method for the next generation of genome-wide
association studies. PLoS Genet., 5, e1000529.
56. Storm, N., Darnhofer-Patel, B., van den Boom, D. and Rodi, C.P. (2003)
MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol.
Biol., 212, 241–262.
Human Molecular Genetics, 2012, Vol. 21, No. 24 5371
57. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. (2007) A
new multipoint method for genome-wide association studies by
imputation of genotypes. Nat. Genet., 39, 906–913.
58. Yang, J., Weedon, M.N., Purcell, S., Lettre, G., Estrada, K., Willer, C.J.,
Smith, A.V., Ingelsson, E., O’Connell, J.R., Mangino, M. et al. (2011)
Genomic inflation factors under polygenic inheritance. Eur. J. Hum.
Genet., 19, 807–812.
59. Li, M.X., Yeung, J.M., Cherny, S.S. and Sham, P.C. (2012) Evaluating the
effective numbers of independent tests and significant p-value thresholds
in commercial genotyping arrays and public imputation reference datasets.
Hum. Genet., 131, 747–756.
60. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt,
T.P., Boehnke, M., Abecasis, G.R. and Willer, C.J. (2010) LocusZoom:
regional visualization of genome-wide association scan results.
Bioinformatics, 26, 2336–2337.
61. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis
and visualization of LD and haplotype maps. Bioinformatics, 21,
263–265.
62. Skol, A.D., Scott, L.J., Abecasis, G.R. and Boehnke, M. (2006) Joint
analysis is more efficient than replication-based analysis for two-stage
genome-wide association studies. Nat. Genet., 38, 209–213.
63. Whitlock, M.C. (2005) Combining probability from independent tests: the
weighted Z-method is superior to Fisher’s approach. J. Evol. Biol., 18,
1368–1373.
APPENDIX
EMINet (Epilepsy and Migraine Integrated Network) Consortium
(participating centers): Cologne Center for Genomics, University of
Cologne, Weyertal 115b, Cologne 50931, Germany (C.L., H.T.,
A-K.R., S.M.P., P.N., T.S.). Department of Epileptology, University
Clinics Bonn, Sigmund Freud Strasse 1, Bonn 53105, Germany
(A.A.K., C.E.E.). Abteilung Neurologie mit Schwerpunkt Epileptolo-
gie, Hertie Institut fu¨r klinische Hirnforschung, Universita¨t Tu¨bingen,
Hoppe-Seyler-Str. 3, Tu¨bingen 72076 (Y.G.W., F.B., H.L.).
EPICURE Integrated Project (participating centers listed by
country): Department of Clinical Neurology (F.Z.) and Department
of Pediatrics and Neonatology (M.M., M.F.), Medical University of
Vienna, Wa¨hringer Gu¨rtel 18-20, A-1090 Vienna, Austria. VIB Depart-
ment of Molecular Genetics, University of Antwerp, Universiteitsplein
1, 2610 Antwerpen, Belgium (Arvid Suls, Sarah Weckhuysen, Lieve
Claes, Liesbet Deprez, Katrien Smets, Tine Van Dyck, Tine Deconinck,
Peter De Jonghe). Department of Neurology, Medical University-Sofia,
Georgi Sofijski Str 1, Sofia 1431, Bulgaria (Reana Velizarova, Petya
Dimova, Melania Radionova, Ivaylo Tournev). Department of Chemis-
try and Biochemistry, Molecular Medicine Center, Medical University-
Sofia, Zdrave Str. 2, Sofia 1431, Bulgaria (Dahlia Kancheva, Radka
Kaneva, A.J.). Research Department, Danish Epilepsy Centre, Diana-
lund Kolonivej 7, Dianalund 4293, Denmark (Rikke S Møller, Helle
Hjalgrim). Wilhelm Johannsen Centre for Functional Genome Re-
search, University of Copenhagen, Blegdamsvej 3, Copenhagen N
2200, Denmark (Rikke S Møller). Neuroscience Center, University of
Helsinki, Biomedicum Helsinki, Haartmaninkatu 8, 00290 Helsinki,
Finland (Anna-Elina Lehesjoki, Auli Siren). Department of Neurope-
diatrics, Hoˆpital Necker-Enfants malades, AP-HP and INSERM
U663, Paris-Descartes University, Paris, France (Rima Nabbout). Epi-
leptology unit, Hoˆpital de la Pitie´-Salpeˆtrie`re, 75013 Paris, France
(Stephanie Baulac, Eric Leguern). Department of Neuropediatrics,
University Medical Center Schleswig-Holstein (Kiel Campus),
Schwanenweg 20, Kiel 24105, Germany (Ingo Helbig, Hiltrud
Muhle, Philipp Ostertag, Sarah von Spiczak, Ulrich Stephani).
Cologne Center for Genomics, University of Cologne, Weyertal
115b, Cologne 50931, Germany (M.L., C.L., A-K.R., S.M.P., T.S.,
M.R.T., H.T., P.N.). Max-Delbru¨ck-Center for Molecular Medicine,
Robert-Ro¨ssle-Strasse 10, Berlin 13125, Germany (Anne Hempel-
mann, Franz Ru¨schendorf, T.S.). Department of Epileptology, Univer-
sity Clinics Bonn, Sigmund Freud Strasse 1, Bonn 53105, Germany
(C.E.E., A.AK.-L, W.S.K., R.S.). Department of Neurology, Charite´
University Medicine, Campus Virchow Clinic, Humboldt University
of Berlin, Augustenburger Platz 1, Berlin 13353, Germany (V.G,,
D.J., T.S., B.S.). Epilepsy-Center Hessen, Department of Neurology,
Philipps-University Marburg, Marburg 35043, Germany (Karl Martin
Klein, Philipp S. Reif, Wolfgang H. Oertel, Hajo M. Hamer, Felix
Rosenow). Abteilung Neurologie mit Schwerpunkt Epileptologie,
Hertie Institut fu¨r klinische Hirnforschung, Universita¨t Tu¨bingen,
Hoppe-Seyler-Str. 3, 72076 Tu¨bingen ( F.B., Y.G.W., H.L.). Child
Neurology Unit, Children’s Hospital A. Meyer, University of Florence,
Florence, Italy (Carla Marini, Reno Guerrini, Davide Mei, Vanessa
Norci). Department of Neuroscience, Institute G. Gaslini (Federico
Zara, Pasquale Striano, Angela Robbiano, Marianna Pezzella), Italian
League Against Epilepsy (A.B., Antonio Gambardella, Paolo
Tinuper, Angela La Neve, Giuseppe Capovilla, Piernanda Vigliano,
Giovanni Crichiutti, Francesca Vanadia, Aglaia Vignoli, Antonietta
Coppola, Salvatore Striano, Gabriella Egeo, Maria Teresa Giallonardo,
Silvana Franceschetti, Vincenzo Belcastro, Paolo Benna, Giangennaro
Coppola, Alessia De Palo, Edoardo Ferlazzo, Marilena Vecchi, Vittorio
Martinelli, Francesca Bisulli, Francesca Beccaria, Ennio Del Giudice,
Margherita Mancardi, Giuseppe Stranci, Aldo Scabar, Giuseppe
Gobbi, Ivan Giordano), Netherlands Section Complex Genetics, De-
partment of Medical Genetics, University Medical Center Utrecht,
Str. 2.112 Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
(B.P.C.K., C.K.F.K, D.L.). SEIN Epilepsy Institute in the Netherlands,
PO Box 540, 2130AM Hoofddorp, The Netherlands (Gerrit-Jan de
Haan). Laboratorio de Neurologia-Unidad de Epilepsia, Servicio de
Neurologia, Instituto Investigacion Sanitaria Fundacion Jimenez
Diaz, and Centro de Investigacion Biomedica en Red de Enfermedades
Raras (CIBERER), Madrid, Spain (Jose M. Serratosa, Rosa Guerrero,
Beatriz G. Giraldez). Department of Genetics, Experimental Medicine
Research Institute (DETAE) and Epilepsy Center (EPIMER) Millet
Cad, Capa 34390, Istanbul, Turkey (Ugur Ozbeck, Nerses Bebek,
Betul Baykan, Ozkan Ozdemir, Sibel Ugur, Elif Kocasoy-Orhan,
Emrah Yu¨cesan, Naci Cine, Aysen Gokyigit, Candan Gurses, Gunay
Gul, Zuhal Yapici, Cigdem Ozkara). Department of Molecular
Biology and Genetics, Bogazici University, Istanbul, Turkey (Hande
Caglayan, Ozlem Yalcin), Department of Neurology, Istanbul
Medical School, Istanbul University (Z.Y.), Department of Neurology,
Sisli Etfal Education Hospital, Istanbul, Turkey (D.A.Y.), Institute of
Neurological Sciences, Marmara University, Maltepe, I˙stanbul,
Turkey (Dilsad Turkdogan), Department of Neurology, Cerrahpasa
Medical School, Istanbul University, Istanbul, Turkey (Cigdem
Ozkara), Ministry of Health Tepecik Education and Research Hospital,
Tepecik, Izmir, Turkey (Gulsen Dizdarer) and Department of Neur-
ology, Marmara University Medical School, Istanbul, Turkey
(Kadriye Agan).
5372 Human Molecular Genetics, 2012, Vol. 21, No. 24
